Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | PSEN1 | P49768 | 18/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 18/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 18/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 18/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 18/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 18/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997802 | 0.88 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1967305 | 0.88 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1967006 | 0.87 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1965749 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1966952 | 0.85 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1965791 | 0.84 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1968448 | 0.83 | PSEN1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1967752 | 0.82 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1966257 | 0.81 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1967711 | 0.81 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389717-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20120190682-A1 | MODULATORS FOR AMYLOID BETA | GOETSCHI ERWIN (CH) | 2012-07-26 | — | — | US | claimed |
| EP-2334665-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20100093731-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | claimed |
| EP-2334665-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-07-10 | — | — | EP | disclosed |
| US-20130143883-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8389717-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389717-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120190682-A1 | MODULATORS FOR AMYLOID BETA | GOETSCHI ERWIN (CH) | 2012-07-26 | — | — | US | disclosed |
| US-20120190682-A1 | MODULATORS FOR AMYLOID BETA | GOETSCHI ERWIN (CH) | 2012-07-26 | — | — | US | disclosed |
| EP-2334665-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-20100093731-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093731-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | disclosed |
| US-20100093731-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2010-04-15 | — | — | US | disclosed |
| WO-2010040661-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010040661-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143883-A1 | MODULATORS FOR AMYLOID BETA | APP, APH1B, APOB | MAPT 55/4885GAA 1082/4885PSEN1 5/4885 |
| US-20120190682-A1 | MODULATORS FOR AMYLOID BETA | APP, APH1B, APOB | MAPT 55/4885GAA 1082/4885PSEN1 5/4885 |
| US-20100093731-A1 | MODULATORS FOR AMYLOID BETA | APP, APH1B, APOB | MAPT 55/4885GAA 1082/4885PSEN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.